12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Grazax: Additional Phase III data

Additional data from a double-blind Phase III trial in 1,501 patients aged 5-65 years with Timothy grass pollen-induced allergic rhinitis with or without conjunctivitis showed that once-daily grass AIT led to a 23% improvement in combined rhinoconjunctivitis DSS and DMS over the entire grass pollen season, the primary endpoint, vs. placebo (p<0.001). On secondary endpoints, grass AIT led to a 20% improvement in DSS over the entire grass pollen season vs. placebo (p=0.001) and a 35% improvement...

Read the full 361 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >